Canaccord Genuity Group Has Lowered Expectations for Candel Therapeutics (NASDAQ:CADL) Stock Price

Key Points

• Canaccord Genuity cut its Candel Therapeutics price target from $25 to $13, but kept a Buy rating; the new target implies about 55% upside from the previous close.
• Analyst sentiment is mixed but leans positive: MarketBeat reports an average “Moderate Buy” rating and a consensus target of $19.29, with nine Buy and two Sell ratings.
• Candel shares opened at $8.39 after a reported 9% decline. The company’s latest quarterly loss of $0.28 per share was narrower than analysts’ estimate of $0.34.

Candel Therapeutics (NASDAQ:CADL - Get Free Report) had its price target decreased by investment analysts at Canaccord Genuity Group from $25.00 to $13.00 in a research report issued on Friday, Benzinga reports. The brokerage presently has a "buy" rating on the stock. Canaccord Genuity Group's target price would indicate a potential upside of 54.95% from the company's previous close.

A number of other equities research analysts have also recently weighed in on the company. UBS Group restated a "buy" rating on shares of Candel Therapeutics in a research note on Monday, August 17th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Candel Therapeutics in a research report on Thursday, October 15th. Bank of America raised shares of Candel Therapeutics from a "neutral" rating to a "buy" rating and increased their price objective for the company from $12.00 to $18.00 in a research report on Monday, September 21st. Wall Street Zen cut shares of Candel Therapeutics from a "hold" rating to a "sell" rating in a research note on Sunday, August 16th. Finally, Jefferies Financial Group began coverage on shares of Candel Therapeutics in a report on Thursday, October 22nd. They set a "buy" rating and a $25.00 target price for the company. Nine research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Candel Therapeutics has an average rating of "Moderate Buy" and an average target price of $19.29.

Candel Therapeutics Trading Down 9.0%

Shares of NASDAQ:CADL opened at $8.39 on Friday. Candel Therapeutics has a 52-week low of $4.35 and a 52-week high of $14.00. The company has a market capitalization of $642.00 million, a P/E ratio of -5.95 and a beta of -0.27. The company has a 50-day simple moving average of $9.89 and a 200 day simple moving average of $8.39. The company has a debt-to-equity ratio of 0.38, a quick ratio of 16.09 and a current ratio of 16.09.

Candel Therapeutics (NASDAQ:CADL - Get Free Report) last announced its quarterly earnings results on Friday, November 13th. The company reported ($0.28) earnings per share for the quarter, topping analysts' consensus estimates of ($0.34) by $0.06. Sell-side analysts forecast that Candel Therapeutics will post -1.29 earnings per share for the current year.

Insider Activity

In other news, CTO Seshu Tyagarajan sold 7,000 shares of the business's stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $12.00, for a total value of $84,000.00. Following the completion of the sale, the chief technology officer owned 76,865 shares of the company's stock, valued at approximately $922,380. The trade was a 8.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 14.30% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Janus Henderson Group PLC bought a new stake in Candel Therapeutics during the 1st quarter worth $845,000. BlackRock Inc. acquired a new position in Candel Therapeutics in the 2nd quarter worth about $51,181,000. Wellington Management Group LLP bought a new position in Candel Therapeutics in the second quarter valued at about $2,119,000. Bank of New York Mellon Corp bought a new position in Candel Therapeutics in the second quarter valued at about $1,975,000. Finally, Squarepoint Ops LLC bought a new position in Candel Therapeutics in the second quarter valued at about $775,000. Institutional investors and hedge funds own 13.93% of the company's stock.

About Candel Therapeutics

Candel Therapeutics is a clinical-stage biotechnology company developing viral immunotherapies designed to stimulate the immune system to fight cancer. Its approach uses engineered viruses to trigger immune responses against tumors. The company's clinical-stage programs include CAN-2409, an adenovirus-based therapy being studied in several solid tumors, and CAN-3110, an oncolytic herpes simplex virus therapy being investigated for recurrent glioblastoma. Based in Needham, Massachusetts, Candel conducts clinical development of its therapies for cancer indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.